Moderna Stock Doubles on Cancer Breakthrough: Hereโs What It Means
A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.
Read from Source ยท decrypt.co ↗
This content is automatically aggregated. Full credit goes to the original publisher (decrypt.co).
